The spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been the primary target of many drug discovery efforts and is similarly utilized in each of the approved COVID-19 ...
In a recent medRxiv* research paper, the US scientists examined the effects of non-synonymous mutations in the circulating B.1.1.7 strain of the severe acute respiratory syndrome coronavirus 2 ...
Characterizing the binding sites of monoclonal antibodies (mAbs) on target antigens, their epitopes, can aid in the discovery and development of new therapeutics, diagnostics, and vaccines. For ...